人类表皮生长因子受体3在人表皮生长因子受体2阳性乳腺癌中的表达及其与预后的关系

目的：探讨人表皮生长因子受体3（human epidermal growth factor receptor-3，HER3）在人表皮生长因子受体2（human epidermal growth factor receptor-2，HER2）阳性乳腺癌中的表达及其与曲妥珠单抗治疗疗效、预后的关系。方法回顾性分析江苏省肿瘤医院2007年1月至2012年6月235例可手术HER2阳性乳腺癌的临床病理资料，免疫组化染色检测手术标本中HER3的表达情况，分析HER3在不同分子亚型HER2阳性乳腺癌中的表达及其与临床病理特征的关系，同时对所有患者进行随访，观察不同HER3表达组的无复发生存时间及其对曲妥珠单抗治疗疗效的影响。结果 HER3在Luminal B （ HER2＋）型乳腺癌中的阳性表达率为74.1％（100/135），在HER2过表达型乳腺癌中的表达率为85.0％（85/100），2者差异具有统计学意义（P＜0.05）。 Luminal B（HER2＋）型乳腺癌中组织学分级、淋巴结转移在不同HER3表达组中差异具有统计学意义（ P＜0.05）。 HER2过表达型乳腺癌中，肿块大小、组织学分级、淋巴结转移在不同HER3表达组中差异具有统计学意义（ P＜0.05）。不同分子亚型的HER2阳性乳腺癌中HER3阴性表达组的5年无复发生存率均高于HER3阳性表达组。在Luminal B（HER2＋）型乳腺癌并接受曲妥珠单抗治疗的患者中，不同HER3表达组的无复发生存时间差异无统计学意义[（26.1±177;0.5）个月vs （21.3±177;0.7）个月，P＝0.080]，但在HER2过表达型乳腺癌患者中不同HER3表达组的无复发生存时间差异具有统计学意义[（26.4±177;0.4）个月vs （23.4±177;0.8）个月，P＝0.036]。结论 HER3与HER2阳性表达乳腺癌的预后不良相关，针对HER3的靶向治疗有望改善HER2和HER3阳性乳腺癌的预后。在HER2过表达型且HER3阴性乳腺癌患者中曲妥珠单抗治疗更能获益。

Expression of HER3 in HER2-positive breast cancer and its relationship with clinical prognosis

Objective To explore the expression of human epidermal growth factor receptor -3（ HER3） in human epidermal growth factor receptor-2（HER2）-positive breast cancer and its relationship with the therapeutic effect of trastuzumab and clinical prognosis .Methods Clinicopathological characteristics of 235 HER2-positive breast cancer patients undergoing surgery in Jiangsu Cancer Hospital from Jan .2007 to Jun.2012 were analyzed retrospectively.The expression of HER3 was detected using immunohistochemisty staining .The expression of HER3 and its correlation with the clinicopathological characteristics were analyzed .All patients were followed-up to find out the impact of HER3 on the disease free survival and the therapeutic effect of trastuzumab .Results The positive rate of HER3 in Luminal B （ HER2 ＋） and HER2-overexpressing breast cancer was 100/135 （74.1%）, and 85/100（85%）respectively.The difference had statistical significance （P＆lt;0.05）.The histolog-ical grading and the lymph node metastasis were significantly different in Luminal B （ HER2＋） breast cancer .The tumor volume , histological grading and lymph node metastasis were significantly different in HER 2-overexpressing breast cancer .The 5-year disease free survival of HER 2-positive breast cancer patients with negative HER 3 was higher than that with positive HER3.The non-relapse survival time was not significantly different between the pos-itive and negative HER 3 expression in Luminal B （ HER2＋） breast cancer patients receiving trastuzumab treat-ment , but was significantly different in HER 2-overexpressing breast cancer patients .Conclusions HER3 is cor-related with unfavourable prognosis in HER 2-positive breast cancer .The treatment targeting HER3 may improve the clinical prognosis of both HER 2-positive and HER3-positive breast cancer patients .The HER2-overexpressing breast cancer patients with negative HER 3 may benefit more from trastuzumab treatment .